01

Jun

2022

12:30

BST

19:30

SGT

Webinar

Inclisiran: A Jab Goes a Long Way

Overview

High levels of low-density lipoprotein (LDL) cholesterol can increase the risk of atherosclerosis and cardiovascular events such as a heart attack or stroke. Inclisiran, now approved by NICE (2021) can be used to reduce LDL cholesterol.

Do you know when, how and on which patients to use the novel anti-cholesterol drug inclisiran to treat elevated LDL in patients with hypercholesterolaemia, mixed dyslipidaemia or patients that have had a previous cardiovascular event?

Join our webinar and learn more during an interactive panel discussion, showcasing real-world case applications of this new agent, produced as part of the ISCP series on the A to Z of CV Pharmacotherapy.

Led by moderators Dr Krittin Bunditakanul (Bangkok, Thailand) and Dr Doreen Tan (Singapore), it includes a speaker presentation from Prof Kyzysztof Filipiak (Warsaw, Poland), two case presentations from Dr Bundaitakanul and discussions from panellists Prof Bernard Cheung (Hong Kong) and Dr Alberto Lorenzatti (Argentina) that will examine the considerations for use of this new agent, through interesting real-world examples, live discussions and audience Q&A.

This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.

Reserve your seat for the next webinar in the series and view on-demand today!

Faculty:


Krzysztof Filipiak

Krzysztof Filipiak


Bernard Man Yung Cheung

Bernard Man Yung Cheung


Alberto Lorenzatti

Alberto Lorenzatti


Krittin Banditanukul

Krittin Banditanukul


Doreen Su-Yin Tan

Doreen Su-Yin Tan

This webinar is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP). The ISCP has been provided support to develop this webinar by Novartis Singapore. The supporter has had no influence on the content of the programme or provided any funding to Radcliffe Cardiology:

Key Learning Objectives

  • To evaluate and understand which patients should and should not receive inclisiran and which patients groups might benefit most
  • To determine how inclisiran should be administered and what dosage adjustments, drug interactions or pharmacogenetic issues need to be noted
  • To analyse special and regional issues that impact the use of this agent and evaluate which groups will benefit most
  • To apply evidence-based recommendations to two real world cases

Target Audience

  • Cardiovascular team members - doctors, nurses and pharmacists
  • Family physicians
  • Internists
  • Cardiovascular pharmacotherapy researchers

Faculty Biographies


Krzysztof Filipiak

Krzysztof Filipiak

Specialist in: cardiology, internal medicine, arterial hypertension, clinical pharmacology (4 certified specializations).

Education: Medical University of Warsaw (MUW), MD, PhD.

Scientific and clinical internships: Medical Faculty, Utrecht University, Netherlands, Medical Faculty, Amsterdam University, Netherlands, Internal Medicine Department, Gaffree e Guinle University, Rio de Janeiro, Brazil, Department of Pharmacology, University of Geneva, Switzerland; Erasmus Programme for University Teachers' Exchange, Milan, Italy; University of Nis, Serbia: visiting professor.

Affiliations: Maria Sklodowska-Curie Medical Academy in Warsaw – Professor and Rector Magnificus since 2021; former: MUW Vice Dean for Science, Medical Faculty 2012-16; Deputy Rector Magnificus, MUW 2016-19; Dean for Science/Medical Sciences Council Chairman in MUW 2019-20;

Medical association memberships: Polish Cardiac Society (PCS): Chairman of Polish Top Junior Cardiologists ,,Club 30” 2007-09; Co-founder and first Chairman of PCS Cardiovascular Pharmacotherapy Working Group 2010-13; Polish Society of Hypertension: President 2018-20; Past-President 2020-22; International Society of Cardiovascular Pharmacotherapy – Governor for Poland 2016 -; European Society of Cardiology - member of the Working Group on Acute Cardiac Care and the Working Group on Cardiovascular Pharmacotherapy; Fellow of European Society of Cardiology 2009;

Research interests: dyslipidaemias, acute coronary syndromes, heart failure, stable angina, cardiovascular pharmacotherapy, renin-angiotensin system, platelets, coagulation, post-COVID, LONG COVID syndromes.

Papers: over 550 indexed in PubMed MEDLINE; according to Google Scholar database (April, 2022): 8016 citations, Hirsch index = 41; i-10 index = 194.

Textbooks: Author and co-author about 100 chapters in monographs and textbooks; co-author and co-editor in Polish e.g.: [Renin-Angiotensin System Drugs], Opolski G, Filipiak KJ, eds., 2000; [Statins - The Basic Clinical Pharmacology], Filipiak KJ, Opolski G, eds., 2001; [Acute Coronary Syndromes], Opolski G, Filipiak KJ, Polonski L, eds., 2002; [Hypertension in oncology], Filipiak KJ, Szymanski FM, Szmit S, eds., 2018. [Coronavirus SARS-CoV-2 textbook], Dzieciatkowski T, Filipiak KJ, eds., 2021.

Former Editor-in-chief (2012-2017): Kardiologia Polska [Polish Heart Journal] – the official journal of Polish Cardiac Society, Executive Editor Cardiology Journal (since 2018-); Editorial Board member of Journal of Cardivascular Development and Disease (IF=3,948).

Tutor experience: 22 PhD, including 12 PhD with special distinction; 12 specialists in cardiology, 7 specialists in internal medicine; reviewer of 56 PhD theses.

Clinical trials experience: ALIVE, ONTARGET/TRANSCEND, IMRPOVE-IT, SIGNIFY, Q-SYMBIO.

View full profile

Bernard Man Yung Cheung

Bernard Man Yung Cheung

Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics and head of the division of Clinical Pharmacology and Therapeutics in the Department of Medicine at the School of Clinical Medicine of the University of Hong Kong.

His research interests include cardiovascular diseases and risk factors such as hypertension and metabolic syndrome.

He is Chief Editor of the Postgraduate Medical Journal (PMJ) and former Chief Editor of Open Diabetes and the World Journal of Hypertension.

View full profile

Alberto Lorenzatti

Alberto Lorenzatti

Dr Alberto J. Lorenzatti heads the Lipid Clinic & Cardiovascular Prevention – Cardiology Department – Hospital Córdoba (Cordoba-Argentina). He also is Co-Director at the DAMIC Medical Institute / Rusculleda Foundation for Research, Teaching and Patient Care (Clinical Research network with more than 50 research sites in Argentina).

University Degrees: Medical Doctor- National Córdoba University, School of Medicine 1980. Specialist in Cardiology - National Córdoba University - 1988. Certified Clinical Lipidologist - Argentine Lipid Society 2014

Academic Background: Invited Professor of Internal Medicine, Universidad Nacional de Córdoba (Argentina), Teacher of Postgraduate Training in Cardiology, Córdoba National University, Hospital Córdoba.

Dr Alberto Lorenzatti is Section Editor of European Cardiology Review.

View full profile

Krittin Banditanukul

Krittin Banditanukul

Dr. Krittin has 15 years’ experience in pharmacy practice, with special interest in cardiovascular, diabetes, emergency, critical care and community pharmacy.

Education: Bachelor of Pharmacy at Huachiew Chalermprakiet University, Doctor of Pharmacy at Chulalongkorn University both located in Thailand.

Training experience: University of Arizona on 2009 and short course training for Emergency and Critical care pharmacotherapy at Kansas in 2014.

Professional affiliation: Committee of College of Pharmacotherapy, Thailand, Committee of Community of Pharmacist for Heart and Vascular, vice president of community pharmacy association of Thailand.

View full profile

Doreen Su-Yin Tan

Doreen Su-Yin Tan

Doreen Tan is an Associate Professor of Clinical & Pharmacy Practice at the National University of Singapore.

Doreen Tan is an Associate Professor of Clinical & Pharmacy Practice at the National University of Singapore. Visiting Cardiology Specialist Pharmacist, National University Hospital Heart Centre, Singapore (NUHCS); Faculty Advisor, NUS Pharmacy Dept Pre-Employment Clinical Training (PECT); Co-Lead, Student-led Collaborative, InnovativePharmacy Inquiry (SCI-PhI) Project, NUS Pharmacy Department; Preceptor, R2 Cardiology Residency Pharmacy Residency Program, Ministry of Health Singapore; Lead,
National Metrics Drug-Related Problems and Productivity committee, Chief PharmacistOffice, Ministry of Health, Singapore; Board of Directors & Singapore Governor,International Society of Cardiovascular Pharmacotherapy; Workgroup Lead for Education (Pharmacy), NUHS Pre-Emptive Pharmacogenomics Steering Committee.

For further information please review her biography in full here: https://pharmacy.nus.edu.sg/team/a-prof-doreen-tan-su-yin/

View full profile